Giles T D, Materson B J, Cohn J N, et al.Definition and classification of hypertension: an update[J]. J Clin Hypertens (Greenwich), 2009, 11(11): 611.
[2]
Lawes C M, Hoorn S V, Rodgers A. Global burden of blood-pressure-related disease, 2001[J]. Lancet, 2008, 371: 1513.
[3]
Ezzati M, Lopez A D, Rodgers A, et al.Comparative risk assessment collaborating group. Selected major risk factors and global and regional burden of disease[J]. Lancet, 2002, 360: 1347.
[4]
Gu D F, Reynolds K, Wu X G, et al. Prevalence, awareness, treatment, and control of hypertension in China[J]. Hypertension, 2002, 40: 920.
[5]
Xiong X J, Yang X C, Liu W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/275279.
[6]
Xiong X J, Yang X C, Liu Y M, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science[J]. Hyperten Res, 2013, 36: 570.
[7]
Wang J, Feng B, Yang X C, et al. Chinese herbal medicine for the treatment of prehypertension[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/493521.
[8]
Wang J, Feng B, Xiong X J. Chinese herbal medicine for the treatment of obesity-related hypertension[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/757540.
[9]
Wang J, Xiong X J. Control strategy on hypertension in Chinese medicine[J]. Evid Based Complement Alternat Med, 2012, doi: 10.1155/2012/284847.
Grassi G, Cattaneo B M. Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension[J]. Hypertension, 1998, 31: 68.
[15]
Binggeli C, Corti R, Sudano I, et al. Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension[J]. Hypertension, 2002, 39: 892.
[16]
Esler M, Straznicky N, Eikelis N. Mechanisms of sympathetic activation in obesity-related hypertension[J]. Hypertension, 2006, 48: 787.
[17]
Schlaich M P, Sobotka P A, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept[J]. Hypertension, 2009, 54(6): 1195.
[18]
DiBona G F. Neural control of the kidney: past, present, and future[J]. Hypertension, 2003, 41: 621.
[19]
Wang J, Feng B, Yang X C, et al. Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/706125.
[20]
Xiong X J, Yang X C, Feng B, et al. Zhen gan xi feng decoction, a traditional Chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/982380.
[21]
熊兴江,李海霞.柴胡加龙骨牡蛎汤证运用体悟[J].上海中医药杂志,2010,44(10):22.
[22]
Wang J, Yang X C, Feng B, et al. Is Yangxue Qingnao granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension[J]. Evid Based Complement Alternat Med, 2013, doi: 10.1155/2013/540613.
Henry V, Carsten O S, Sebastian E B, et al. Personalized cardiovascular medicine: concepts and methodological considerations[J]. Nat Rev Cardiol, 2013, 10: 308.
[28]
Chehl N, Gong Q, Chipitsyna G, et al. Angiotensin Ⅱ regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells[J].J Gastrointest Surg, 2009, 13(12): 2189.
[29]
Miyajima A, Kikuchi E, Kosaka T, et al. Angiotensin Ⅱ type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer[J]. Rev Recent Clin Trials, 2009, 4(2): 75.
[30]
Xu H, Chen K J. Complementary and alternative medicine: is it possible to be mainstream?[J]. Chin J Integrat Med, 2012, 18: 403.
